Journal ArticleDOI
Use of Non-Nucleoside Analogues Together with Rifampin in HIV Patients with Tuberculosis
J Villar,P. Sánchez,Alicia González,Luisa Sorlí,Milagro Montero,Ana Guelar,E. Solé,J. L. López,Hernando Knobel +8 more
Reads0
Chats0
TLDR
The effectiveness of NVP and nonadjusted EFV was lower than adjusted EFV-based ART and it may be advisable to increase the dose of EFV to 800 mg once daily when administered with rifampin in patients weighing >60 kg.Abstract:
Objective: The concomitant use of rifampin (RFP) with efavirenz (EFV) or nevirapine (NVP) is frequent in HIV patients with tuberculosis (TB). The necessity of increasing the dose of EFV remains controversial. The aim of the study was to evaluate the outcome of HIV infection in patients treated with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) and RFR. Methods: Retrospective analysis of HIV patients who were simultaneously treated with RFP and NVP or EFV. The dose of EFV was considered to be adjusted in those patients receiving 600 mg when weighing 60 kg and was considered nonad-justed when the dose given was 600 mg in patients >60 kg.Results: 63 patients were included: 13 received NVP and 50 received EFV-based ART (30 adjusted and 20 nonadjusted). Treatment failure was observed in 7 (53.8%) of the NVP group; 11 (55%) of the nonadjusted EFV group, and 8 (26.7%) of the adjusted EFV group (P = .04). The relative risk (RR) of treatment...read more
Citations
More filters
Journal ArticleDOI
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
Prinitha Pillay,Prinitha Pillay,Prinitha Pillay,Nathan Ford,Nathan Ford,Zara Shubber,Rashida A. Ferrand +6 more
TL;DR: EFV-based first line ART is significantly less likely to lead to virologic failure compared to NVP-based ART, and this finding supports the use of EFV as the preferred NNRTI in first-line treatment regimen for HIV treatment, particularly in resource limited settings.
Journal ArticleDOI
Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.
Hadija H. Semvua,Gibson S. Kibiki,Elton R. Kisanga,Martin J. Boeree,David M. Burger,Rob E. Aarnoutse +5 more
TL;DR: The current research priorities can be addressed by maximizing the use of already existing data, creating new data by conducting clinical trials and prospective observational studies and to engage a lobby to make currently unavailable drugs available to those most in need.
Journal ArticleDOI
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial
Olivier Lortholary,Caroline Roussillon,Céline Boucherie,Christophe Padoin,Marie-Laure Chaix,Guillaume Breton,Agathe Rami,Nicolas Veziris,O. Patey,Eric Caumes,Thierry May,Jean-Michel Molina,Jérôme Robert,Michel Tod,Catherine Fagard,Geneviève Chêne +15 more
TL;DR: These results support the use of tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients with TB.
Journal ArticleDOI
Issues in resistance, adherence, and comparative efficacy of the single- tablet regimen combination of tenofovir, emtricitabine, and efavirenz in the management of HIV-1 infection
Gabriel Rebick,Sharon Walmsley +1 more
TL;DR: Atripla is the first once-daily, single- tablet, triple-combination antiretroviral therapy based on its proven efficacy in numerous head-to-head randomized clinical trials, and has resulted in an improvement in adherence, quality of life, and satisfaction among naive as well as virally suppressed patients switching from another regimen.
References
More filters
Journal ArticleDOI
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
Brian Gazzard,Jane Anderson,Abdel Babiker,Marta Boffito,Gary Brook,Gary Brough,Duncan Churchill,Ben Cromarty,Satyajit Das,Martin Fisher,Andrew L. Freedman,Anna Maria Geretti,Margaret A. Johnson,Saye Khoo,Clifford Leen,Devaki Nair,Barry Peters,Andrew N. Phillips,Deenan Pillay,Anton Pozniak,John P. Walsh,Ed Wilkins,Ian S. Williams,Matthew Williams,M Youle +24 more
TL;DR: The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information since the last iteration and all the peer-reviewed publications and important, potentially treatment-changing abstracts from the last 2 years have been reviewed.
Journal ArticleDOI
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Andrew Boulle,Gilles van Cutsem,Karen Cohen,Katherine Hilderbrand,Shaheed Mathee,Musaed Abrahams,Eric Goemaere,David Coetzee,Gary Maartens +8 more
TL;DR: In this cohort study, virological outcomes were inferior when nevirapine-based antiretroviral therapy was commenced while taking antitubercular treatment but comparable when starting efavirenz-based anti-cancer therapy and rifampicin-based antituberculosis therapy.
Journal ArticleDOI
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
Esteban Ribera,Leonor Pou,Rosa M Lopez,Manuel Crespo,Vicenç Falcó,Imma Ocaña,Isabel Ruiz,Albert Pahissa +7 more
TL;DR: Given that the lowest trough serum concentration of nevirapine exceeded by more than 40 times the protein binding adjusted median infective dose (IC(50) of wild-type HIV in all patients, it is suggested that there is no need to increase nevirAPine dosage when it is given with rifampicin.
Journal ArticleDOI
Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.
TL;DR: This research presents a novel and scalable approach that aims to provide real-time information about the immune response to chemotherapy-like symptoms in patients with central giant cell granuloma.
Journal ArticleDOI
A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse-Transcriptase Inhibitor-Based Regimens in HIV-Infected Patients Receiving Rifampicin: The N2R Study
Weerawat Manosuthi,Weerawat Manosuthi,Somnuek Sungkanuparph,Preecha Tantanathip,Aroon Lueangniyomkul,Wiroj Mankatitham,Wisit Prasithsirskul,Sunantha Burapatarawong,Supeda Thongyen,Sirirat Likanonsakul,Unchana Thawornwa,Vilaiwan Prommool,Kiat Ruxrungtham +12 more
TL;DR: Antiretroviral therapy regimens containing efavirenz (600 mg per day) were less compromised by concomitant use of rifampicin than were those that contained nevirapine (400 mg perday) in patients with concurrent HIV-1 infection and TB.